Caelus Life Sciences Holding Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

  • Latest Deal Amount
  • $30M

  • Investors
  • 3

Caelus Life Sciences Holding General Information

Description

Developer of microbiome-based therapeutics designed to be used for early intervention in cardiometabolic disorders. The company's therapeutics include single-strain products that target pre-diabetes, increase the sensitivity for insulin and aim to delay the onset of diabetes in people who are overweight and have an increased risk for cardiovascular disorders, enabling patients to have a range of microbiota-based products as therapy in diabetes and late-stage cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • PO Box 302
  • 1850 AH Heiloo
  • Netherlands
+31 06
Primary Industry
Drug Discovery
Other Industries
Food Products
Corporate Office
  • PO Box 302
  • 1850 AH Heiloo
  • Netherlands
+31 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Caelus Life Sciences Holding Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC $30M Cancelled Generating Revenue
6. Secondary Transaction - Private Completed Clinical Trials - Phase 2
5. Later Stage VC 01-Dec-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC 30-Nov-2019 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 26-Jan-2017 Completed Pre-Clinical Trials
2. Debt - General $2.03M $3.4M Completed Startup
1. Early Stage VC 01-Jan-2014 $1.37M $1.37M Completed Startup
To view Caelus Life Sciences Holding’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Caelus Life Sciences Holding Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of microbiome-based therapeutics designed to be used for early intervention in cardiometabolic disorders. The
Drug Discovery
Heiloo, Netherlands
5 As of 2023

King of Prussia, PA
 

Carlsbad, CA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Caelus Life Sciences Holding Competitors (17)

One of Caelus Life Sciences Holding’s 17 competitors is XyloCor Therapeutics, a Venture Capital-Backed company based in King of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
XyloCor Therapeutics Venture Capital-Backed King of Prussia, PA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Lexeo Therapeutics Formerly VC-backed New York, NY
Cytokinetics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 17 competitors. Get the full list »

Caelus Life Sciences Holding Patents

Caelus Life Sciences Holding Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023099579-A1 Prevention or treatment of hepatic steatosis Inactive 03-Dec-2021
WO-2022248588-A1 Insulin-sensitizing agent and butyrate-producing bacterium Inactive 28-May-2021
WO-2022063980-A1 Fecal matter for preventing or treating intestinal microbiome aberrations in cesarean section born infants Inactive 25-Sep-2020
JP-2022031800-A Compositions and methods for preventing and / or treating vitamin b12 deficiency Active 25-Feb-2016
AU-2017222990-A1 Compositions and methods for preventing and/or treating vitamin b12 deficiency Inactive 25-Feb-2016 A61K35/74
To view Caelus Life Sciences Holding’s complete patent history, request access »

Caelus Life Sciences Holding Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Caelus Life Sciences Holding Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amsterdam UMC Ventures Holding Venture Capital Minority
UvA Ventures Holding Venture Capital Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
To view Caelus Life Sciences Holding’s complete investors history, request access »

Caelus Life Sciences Holding FAQs

  • When was Caelus Life Sciences Holding founded?

    Caelus Life Sciences Holding was founded in 2014.

  • Where is Caelus Life Sciences Holding headquartered?

    Caelus Life Sciences Holding is headquartered in Heiloo, Netherlands.

  • What is the size of Caelus Life Sciences Holding?

    Caelus Life Sciences Holding has 5 total employees.

  • What industry is Caelus Life Sciences Holding in?

    Caelus Life Sciences Holding’s primary industry is Drug Discovery.

  • Is Caelus Life Sciences Holding a private or public company?

    Caelus Life Sciences Holding is a Private company.

  • What is the current valuation of Caelus Life Sciences Holding?

    The current valuation of Caelus Life Sciences Holding is .

  • What is Caelus Life Sciences Holding’s current revenue?

    The current revenue for Caelus Life Sciences Holding is .

  • How much funding has Caelus Life Sciences Holding raised over time?

    Caelus Life Sciences Holding has raised $6.93M.

  • Who are Caelus Life Sciences Holding’s investors?

    Amsterdam UMC Ventures Holding, UvA Ventures Holding, and Johnson & Johnson JJDC have invested in Caelus Life Sciences Holding.

  • Who are Caelus Life Sciences Holding’s competitors?

    XyloCor Therapeutics, Renova Therapeutics, Voyager Therapeutics, Lexeo Therapeutics, and Cytokinetics are some of the 17 competitors of Caelus Life Sciences Holding.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process